3-肼基吡啶 | 42166-50-7

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-肼基吡啶
• 中文别名: 3-肼基吡啶双盐酸盐；3-肼基吡啶二盐酸盐
• 英文名称: 3-hydrazinopyridine
• 英文别名: 3-hydrazinylpyridine；3-hydrazineylpyridine；3-Hydrazino-pyridin；pyridin-3-ylhydrazine
• CAS: 42166-50-7
• 化学式: C₅H₇N₃
• mdl: MFCD07786306
• 分子量: 109.131
• InChiKey: RCIGDGBXEMECGY-UHFFFAOYSA-N

物化性质

• 熔点：
  53-55 °C
• 沸点：
  286.4±13.0 °C(Predicted)
• 密度：
  1.222

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.9
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存于室温、避光且在惰性气体环境中

反应信息

• 作为反应物：
  描述：

  3-肼基吡啶 在 三乙胺 作用下， 以 乙醇 为溶剂， 生成 1,5-二氢-1-(3-吡啶)-4H-吡唑并[3,4-d]嘧啶-4-酮
  参考文献：
  名称：

  新型GLUT抑制剂的鉴定

  摘要：

  使用HTS将1 H-吡唑并[3,4- d ]嘧啶类化合物鉴定为促进葡萄糖转运蛋白1（GLUT1）的非常有效的抑制剂。建立了分子框架每个环系统的广泛结构-活性关系研究（SAR），揭示了必要的结构动机（即，邻甲氧基取代的苯，哌嗪和嘧啶）。对GLUT2的选择性非常好，并且最初的体外和体内药代动力学（PK）研究令人鼓舞。

  DOI：

  10.1016/j.bmcl.2016.02.050
• 作为产物：
  描述：

  3-羟基吡啶 在 一水合肼 作用下， 反应 10.0h， 生成 3-肼基吡啶
  参考文献：
  名称：

  A novel potent metal-binding NDM-1 inhibitor was identified by fragment virtual, SPR and NMR screening

  摘要：

  NDM-1 can hydrolyze nearly all available β-lactam antibiotics, including carbapenems. NDM-1 producing bacterial strains are worldwide threats. It is still very challenging to find a potent NDM-1 inhibitor for clinical use. In our study, we used a metal-binding pharmacophore (MBP) enriched virtual fragment library to screen NDM-1 hits. SPR screening helped to verify the MBP virtual hits and identified a new NDM-1 binder and weak inhibitor A1. A solution NMR study of ¹⁵N-labeled NDM-1 showed that A1 disturbed all three residues coordinating the second zinc ion (Zn2) in the active pocket of NDM-1. The perturbation only happened in the presence of zinc ion, indicating that A1 bound to Zn2. Based on the scaffold of A1, we designed and synthesized a series of NDM-1 inhibitors. Several compounds showed synergistic antibacterial activity with meropenem against NDM-1 producing K. pneumoniae.

  DOI：

  10.1016/j.bmc.2020.115437

文献信息

• Isoquinoline-1,3-diones as Selective Inhibitors of Tyrosyl DNA Phosphodiesterase II (TDP2)
  作者：Jayakanth Kankanala、Christophe Marchand、Monica Abdelmalak、Hideki Aihara、Yves Pommier、Zhengqiang Wang

  DOI：10.1021/acs.jmedchem.5b01973

  日期：2016.3.24

  isoquinoline-1,3-dione as a viable chemotype for selectively inhibiting TDP2. The initial hit compound 43 was identified by screening our in-house collection of synthetic compounds. Further structure–activity relationship (SAR) studies identified numerous analogues inhibiting TDP2 in low micromolar range without appreciable inhibition against the homologous TDP1 at the highest testing concentration

  酪氨酰DNA磷酸二酯酶II（TDP2）是最近发现的一种酶，可特异性修复拓扑异构酶II（Top2）毒物引起的DNA损伤并引起对这些药物的耐药性。预期抑制TDP2可增强临床上重要的靶向Top2的抗癌药的功效。但是，作为治疗靶标的TDP2仍然知之甚少。我们在此报告了异喹啉-1,3-二酮作为选择性抑制TDP2的可行化学型的发现。最初的打击化合物43通过筛选我们内部的合成化合物来鉴定。进一步的结构活性关系（SAR）研究发现，在最高测试浓度（111μM）下，许多类似物在低微摩尔范围内抑制TDP2，而对同源TDP1没有明显的抑制作用。最佳化合物64抑制重组TDP2，IC 50为1.9μM 。这种化学型的发现可以为理解TDP2作为药物靶标提供一个平台。
• PYRAZOLE DERIVATIVES
  申请人：DAIICHI PHARMACEUTICAL CO., LTD.

  公开号：EP1762568A1

  公开（公告）日：2007-03-14

  A compound represented by formula (I): (wherein Ar1 represents a phenyl group which may have 1 to 3 substituents, or a non-substituted 5- or 6-membered aromatic heterocyclic group; Ar2 represents (i) a non-substituted phenyl group, (ii) a phenyl group which has been substituted by a lower alkyl group having 1 to 3 groups or atoms selected from among a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom, or (iii) a 5- or 6-membered nitrogen-containing aromatic heterocyclic group which has been substituted by 1 to 3 groups or atoms selected from among a lower alkyl group, a lower alkynyl group, a lower alkanoyl group, a carbamoyl group, a cyano group, an amino group, a hydroxyl group, a lower alkoxy group, and a halogen atom; and X represents a group represented by formula (II): (wherein the ring structure represents a 4- to 7-membered heterocyclic group which may have, in addition to the nitrogen atom shown in formula (II), one heteroatom selected from among nitrogen, oxygen, and sulfur, and which may be substituted by 1 to 4 groups or atoms selected from among a lower alkyl group, a carbamoyl group, an amino group, a hydroxyl group, a lower alkoxy group, an oxo group, a lower alkanoyl group, a lower alkylsulfonyl group, and a halogen atom)), a salt thereof, a solvate of the compound or the salt, and a drug.

  由式(I)表示的化合物： （其中Ar1代表可能具有1到3个取代基的苯基，或者是非取代的5-或6-成员芳香杂环基团；Ar2代表（i）非取代的苯基团，（ii）已被1到3个来自羰胺基、氨基、羟基、低烷氧基和卤原子的群或原子取代的较低烷基基团取代的苯基团，或者（iii）已被1到3个来自低烷基基团、低炔基基团、低烷酰基团、羰胺基、氰基、氨基、羟基、低烷氧基和卤原子的群或原子取代的5-或6-成员含氮芳香杂环基团；X代表由式(II)表示的基团： （其中环结构表示可能具有除了式(II)中显示的氮原子之外，从氮、氧和硫中选择的一个杂原子的4-到7-成员杂环基团，并且可能被1到4个来自低烷基基团、羰胺基、氨基、羟基、低烷氧基、氧基、低烷酰基团、低烷基磺酰基团和卤原子的群或原子取代）），其盐，该化合物或其盐的溶剂化合物，以及药物。
• Heterocyclic Compounds as Pesticides
  申请人：BRETSCHNEIDER Thomas

  公开号：US20110166143A1

  公开（公告）日：2011-07-07

  The present application relates to the use of heterocyclic compounds, some of which are known, for controlling animal pests including arthropods and in particular insects, furthermore to novel heterocyclic compounds and to processes for their preparation.

  本申请涉及使用杂环化合物来控制动物害虫，包括节肢动物，特别是昆虫，此外还涉及新型杂环化合物及其制备方法。
• Indolythiadiazines for treating heart failure
  申请人：Les Laboratoires Beecham S.A.

  公开号：US05051417A1

  公开（公告）日：1991-09-24

  A compound of formula (I) or a pharmaceutically acceptable salt thereof, ##STR1## in which, R.sub.1 is hydrogen or lower alkyl; R.sub.2 is hydrogen or lower alkyl; R.sub.4 and R.sub.4 ' together form a group .dbd.N--Ra, or .dbd.CRaRb, where Ra is hydrogen, lower alkyl, aryl, aryloxy, lower alkylcarbonyl, arylcarbonyl, aryloxycarbonyl, lower alkoxy, lower alkoxy carbonyl, lower alkoxy carbonyl alkoxy, lower thioalkoxy, hydroxy, nitrile, heterocyclyl, or --NRcRd, where Rc is hydrogen, lower alkyl, cycloalkyl, aryl, aralkyl, lower alkylcarbonyl, arylcarbonyl, aminocarbonyl, aminothiocarbonyl, aminoiminocarbonyl, lower alkoxycarbonyl, lower alkoxythiocarbonyl, aryloxycarbonyl, thiocarbonyl, nitrile, carboxyl, heterocyclyl or heterocyclylcarbonyl, and Rd is hydrogen or lower alkyl; Rb is hydrogen, lower alkyl, aryl, lower alkylcarbonyl, lower alkoxycarbonyl, nitrile or nitro; or R.sub.4 is --NH--Ra, in which Ra is as defined above, and R.sub.4 ' is hydrogen or lower alkyl; each of R.sub.3 and R.sub.5 is independently hydrogen, lower alkyl, aryl, lower alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, heterocyclylcarbonyl, optionally substituted aminocarbonyl, lower alkoxycarbonyl or aryloxycarbonyl; R.sub.6 is hydrogen, lower alkyl or halogen; and A is sulphur, oxygen, --NH-- or --CH.sub.2 --, is useful for the treatment of heart disease.

  化合物的化学式（I）或其药学上可接受的盐，其中，R.sub.1为氢或较低的烷基；R.sub.2为氢或较低的烷基；R.sub.4和R.sub.4'共同形成一个基团.dbd.N--Ra，或.dbd.CRaRb，其中Ra为氢，较低的烷基，芳基，芳氧基，较低的烷基羰基，芳基羰基，芳氧羰基，较低的烷氧基，较低的烷氧羰基，较低的烷氧羰基烷氧基，较低的硫代烷氧基，羟基，腈基，杂环烷基，或--NRcRd，其中Rc为氢，较低的烷基，环烷基，芳基，芳基烷基，较低的烷基羰基，芳基羰基，氨基羰基，氨基硫代羰基，氨基亚胺羰基，较低的烷氧羰基，较低的烷氧硫代羰基，芳氧羰基，硫代羰基，腈基，羧基，杂环烷基或杂环烷基羰基，且Rd为氢或较低的烷基；Rb为氢，较低的烷基，芳基，较低的烷基羰基，较低的烷氧羰基，腈基或硝基；或R.sub.4为--NH--Ra，其中Ra如上定义，且R.sub.4'为氢或较低的烷基；R.sub.3和R.sub.5中的每一个独立地为氢，较低的烷基，芳基，较低的烷基羰基，芳基羰基，芳基烷基羰基，杂环烷基羰基，可选择地取代的氨基羰基，较低的烷氧羰基或芳氧羰基；R.sub.6为氢，较低的烷基或卤素；A为硫，氧，--NH--或--CH.sub.2--，用于治疗心脏病。
• [EN] 1,3-SUBSTITUED PYRAZOLE COMPOUNDS USEFUL FOR REDUCTION OF VERY LONG CHAIN FATTY ACIC LEVELS<br/>[FR] COMPOSÉS PYRAZOLE 1,3-SUBSTITUÉS UTILES POUR LA RÉDUCTION DE NIVEAUX D'ACIDES GRAS À CHAÎNE TRÈS LONGUE
  申请人：VERTEX PHARMA

  公开号：WO2018107056A1

  公开（公告）日：2018-06-14

  Disclosed are chemical entities which are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein Formula (I) has the structure: R1a, R1b, R2, R3, R4a, R4b and Y are as defined herein. These chemical entities are useful for reduction of very long chain fatty acid levels. These chemical entities and pharmaceutically acceptable compositions comprising such chemical entities can be useful for treating various diseases, disorders and conditions, such as adrenoleukodystrophy (ALD).

  揭示了化学实体，它们是具有式（I）的化合物及其药学上可接受的盐，其中式（I）具有结构：R1a，R1b，R2，R3，R4a，R4b和Y如本文所定义。这些化学实体对于降低非常长链脂肪酸水平是有用的。这些化学实体和包括这些化学实体的药学上可接受的组合物可用于治疗各种疾病、疾病和症状，如肾上腺白质脑白质营养不良（ALD）。